Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Ethanol Consumption in Mice Lacking CD14, TLR2, TLR4, or MyD88.

Blednov YA, Black M, Chernis J, Da Costa A, Mayfield J, Harris RA.

Alcohol Clin Exp Res. 2017 Mar;41(3):516-530. doi: 10.1111/acer.13316. Epub 2017 Feb 1.

PMID:
28146272
2.

Alcohol use dependence in fragile X syndrome.

Salcedo-Arellano MJ, Lozano R, Tassone F, Hagerman RJ, Saldarriaga W.

Intractable Rare Dis Res. 2016 Aug;5(3):207-13. doi: 10.5582/irdr.2016.01046.

3.

Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice.

Ho AM, Qiu Y, Jia YF, Aguiar FS, Hinton DJ, Karpyak VM, Weinshilboum RM, Choi DS.

Alcohol Clin Exp Res. 2016 Jul;40(7):1531-9. doi: 10.1111/acer.13099. Epub 2016 May 17.

4.

Genes and Alcohol Consumption: Studies with Mutant Mice.

Mayfield J, Arends MA, Harris RA, Blednov YA.

Int Rev Neurobiol. 2016;126:293-355. doi: 10.1016/bs.irn.2016.02.014. Review.

5.

Group 1 mGlu-family proteins promote neuroadaptation to ethanol and withdrawal-associated hippocampal damage.

Reynolds AR, Williams LA, Saunders MA, Prendergast MA.

Drug Alcohol Depend. 2015 Nov 1;156:213-20. doi: 10.1016/j.drugalcdep.2015.09.013. Epub 2015 Sep 26.

6.

Frequency of alcohol consumption in humans; the role of metabotropic glutamate receptors and downstream signaling pathways.

Meyers JL, Salling MC, Almli LM, Ratanatharathorn A, Uddin M, Galea S, Wildman DE, Aiello AE, Bradley B, Ressler K, Koenen KC.

Transl Psychiatry. 2015 Jun 23;5:e586. doi: 10.1038/tp.2015.70.

7.

Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans.

Blednov YA, Benavidez JM, Black M, Ferguson LB, Schoenhard GL, Goate AM, Edenberg HJ, Wetherill L, Hesselbrock V, Foroud T, Harris RA.

Alcohol Clin Exp Res. 2015 Jan;39(1):136-45. doi: 10.1111/acer.12610. Epub 2014 Dec 16.

8.

Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers.

Polussa J, Schneider A, Hagerman R.

Brain Disord Ther. 2014;3. pii: 1000119.

9.

Molecular basis of alcoholism.

Most D, Ferguson L, Harris RA.

Handb Clin Neurol. 2014;125:89-111. doi: 10.1016/B978-0-444-62619-6.00006-9. Review.

10.

Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker.

Erickson CA, Ray B, Maloney B, Wink LK, Bowers K, Schaefer TL, McDougle CJ, Sokol DK, Lahiri DK.

J Psychiatr Res. 2014 Dec;59:220-8. doi: 10.1016/j.jpsychires.2014.07.011. Epub 2014 Aug 19.

11.

The development of acamprosate as a treatment against alcohol relapse.

Kufahl PR, Watterson LR, Olive MF.

Expert Opin Drug Discov. 2014 Nov;9(11):1355-69. doi: 10.1517/17460441.2014.960840. Epub 2014 Sep 26. Review.

12.

Neurotransmitters in alcoholism: A review of neurobiological and genetic studies.

Banerjee N.

Indian J Hum Genet. 2014 Jan;20(1):20-31. doi: 10.4103/0971-6866.132750. Review.

13.

Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice.

Blednov YA, Benavidez JM, Black M, Harris RA.

Front Neurosci. 2014 May 27;8:129. doi: 10.3389/fnins.2014.00129. eCollection 2014 May 27.

14.

Pharmacological approaches to reducing craving in patients with alcohol use disorders.

Haass-Koffler CL, Leggio L, Kenna GA.

CNS Drugs. 2014 Apr;28(4):343-60. doi: 10.1007/s40263-014-0149-3. Review.

15.

Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models.

Doll CA, Broadie K.

Front Cell Neurosci. 2014 Feb 7;8:30. doi: 10.3389/fncel.2014.00030. eCollection 2014 Feb 7. Review.

16.

Pharmacotherapy of alcohol use disorders: seventy-five years of progress.

Zindel LR, Kranzler HR.

J Stud Alcohol Drugs Suppl. 2014;75 Suppl 17:79-88. Review.

17.

Positively correlated miRNA-mRNA regulatory networks in mouse frontal cortex during early stages of alcohol dependence.

Nunez YO, Truitt JM, Gorini G, Ponomareva ON, Blednov YA, Harris RA, Mayfield RD.

BMC Genomics. 2013 Oct 22;14:725. doi: 10.1186/1471-2164-14-725.

18.

Glutamatergic targets for new alcohol medications.

Holmes A, Spanagel R, Krystal JH.

Psychopharmacology (Berl). 2013 Oct;229(3):539-54. doi: 10.1007/s00213-013-3226-2. Epub 2013 Sep 1. Review.

19.

Pharmacotherapies for Overeating and Obesity.

Yarnell S, Oscar-Berman M, Avena N, Blum K, Gold M.

J Genet Syndr Gene Ther. 2013 Apr 1;4(3):131.

20.

The clinical pharmacology of acamprosate.

Kalk NJ, Lingford-Hughes AR.

Br J Clin Pharmacol. 2014 Feb;77(2):315-23. doi: 10.1111/bcp.12070. Review.

Supplemental Content

Support Center